Abstract
Purpose
Methods
Results
Conclusion
Keywords
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of MedicineReferences
- An observational study of dyspnea in emergency departments: the Asia, Australia, and New Zealand Dyspnea in Emergency Departments Study (AANZDEM).Acad Emerg Med. 2017; 24: 328-336
- Epidemiology of patients presenting with dyspnea to emergency departments in Europe and the Asia-Pacific region.Eur J Emerg Med. 2019; 26: 345-349
- Readmission following both cardiac and non-cardiac acute dyspnoea is associated with a striking risk of death.ESC Heart Fail. 2021; 8: 2473-2484
- Signs and symptoms in adult patients with acute dyspnea: a systematic review and meta-analysis.Eur J Emerg Med. 2018; 25: 3-11
- Overcrowding in emergency departments: a review of strategies to decrease future challenges.J Res Med Sci. 2017; 22: 23
- Evaluating biomarkers for guiding treatment decisions.EJIFCC. 2015; 26: 63-70
- Adrenomedullin: a marker of impaired hemodynamics, organ dysfunction, and poor prognosis in cardiogenic shock.Ann Intensive Care. 2017; 7: 6
- Elevated plasma bioactive adrenomedullin and mortality in cardiogenic shock: results from the OptimaCC trial.J Clin Med. 2021; 10: 4512
- Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure.Eur J Heart Fail. 2019; 21: 732-743
- Circulating biologically active adrenomedullin predicts organ failure and mortality in sepsis.Ann Lab Med. 2019; 39: 454-463
Self WH, Storrow AB, Hartmann O, et al. Plasma bioactive-adrenomedullin as a prognostic biomarker in acute heart failure. Am J Emerg Med. 2016;34(2):257-262.
- Determinants of long-term outcome in ICU survivors: results from the FROG-ICU study.Crit Care. 2018; 22: 1-10
- Circulating biologically active adrenomedullin (bio-ADM) predicts hemodynamic support requirement and mortality during sepsis.Chest. 2017; 152: 312-320
- Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: The prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1 (AdrenOSS-1) study.Crit Care. 2018; 22: 1-12
- Bio-adrenomedullin as a potential quick, reliable, and objective marker of congestion in heart failure.Eur J Heart Fail. 2018; 20: 1363-1365
- Bioactive adrenomedullin, proenkephalin A and clinical outcomes in an acute heart failure setting.Open Heart. 2019; 6e001048
- Adrenomedullin in heart failure: pathophysiology and therapeutic application.Eur J Heart Fail. 2019; 21: 163-171
- Activity of the adrenomedullin system to personalise post-discharge diuretic treatment in acute heart failure.Clin Res Cardiol. 2021; ([online ahead of print]) (Jul 23)https://doi.org/10.1007/s00392-021-01909-9
- Circulating bioactive adrenomedullin as a marker of sepsis, septic shock and critical illness.Crit Care. 2020; 24: 1-10
- Sandwich immunoassay for bioactive plasma adrenomedullin.J Appl Lab Med. 2017; 2: 222-233
- Guidelines for the echocardiographic assessment of the right heart in adults: a Report from the American Society of Echocardiography: endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography.J Am Soc Echocardiogr. 2010; 23: 685-713
- Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma.Biochem Biophys Res Commun. 1993; 192: 553-560
- Mid-regional pro-adrenomedullin outperforms N-terminal pro-B-type natriuretic peptide for the diagnosis of acute heart failure in the presence of atrial fibrillation.Eur J Heart Fail. 2020; 22: 692-700
- Prognostic potential of midregional pro-adrenomedullin following decompensation for systolic heart failure: comparison with cardiac natriuretic peptides.Eur J Heart Fail. 2017; 19: 1166-1175
- Prognostic value of mid-regional pro-adrenomedullin (MR-proADM) in patients with community-acquired pneumonia: a systematic review and meta-analysis.BMC Infect Dis. 2016; 16: 232
- Pro-Adrenomedullin predicts 10-year all-cause mortality in community-dwelling patients: a prospective cohort study.BMC Cardiovasc Disord. 2017; 17: 178
- New role of biomarkers: mid-regional pro-adrenomedullin, the biomarker of organ failure.Ann Transl Med. 2016; 4: 329
- Adrenomedullin optimises mortality prediction in COPD patients.Respir Med. 2015; 109: 734-742
- Midregional proadrenomedullin (MR-proADM) in the risk stratification of patients with acute pulmonary embolism.Thromb Res. 2013; 132: 506-510
- The TRIAGE-ProADM score for an early risk stratification of medical patients in the emergency department - development based on a multi-national, prospective, observational study.PLoS One. 2016; 11e0168076
- Combination of the National Early Warning Score (NEWS) and inflammatory biomarkers for early risk stratification in emergency department patients: results of a multinational, observational study.BMJ Open. 2019; 9e024636
- Prognostic value of different biomarkers for cardiovascular death in unselected older patients in the emergency department.Eur Heart J Acute Cardiovasc Care. 2016; 5: 568-578
- The early identification of disease progression in patients with suspected infection presenting to the emergency department: a multi-centre derivation and validation study.Crit Care. 2019; 23: 1-15
- Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial.J Am Coll Cardiol. 2010; 55: 2062-2076
- Midregional pro-adrenomedullin in addition to b-type natriuretic peptides in the risk stratification of patients with acute dyspnea: an observational study.Crit Care. 2009; 13: R122
- Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea.Eur Heart J. 2012; 33: 2197-2205
- Evaluation of mid-regional pro-atrial natriuretic peptide, procalcitonin, and mid-regional pro-adrenomedullin for the diagnosis and risk stratification of dyspneic ED patients.Am J Emerg Med. 2012; 30: 1915-1920
- Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial.Am J Emerg Med. 2014; 32: 334-341
- MR-proANP, MR-proADM, and PCT in patients presenting with acute dyspnea in a medical emergency unit.Lung. 2016; 194: 185-191
Hausfater P, Claessens YE, Martinage A, et al. Prognostic value of PCT, copeptin, MR-proADM, MR-proANP and CT-proET-1 for severe acute dyspnea in the emergency department: the BIODINER study. Biomarkers. 2016;22(1):28-34.
- Evaluation of eight biomarkers to predict short-term mortality in patients with acute severe dyspnea.Minerva Anestesiologica. 2017; 83: 824-835
- Bioactive adrenomedullin in plasma is associated with biventricular filling pressures in patients with advanced heart failure.Eur J Heart Fail. 2021; 23: 489-491
Sugo S, Minamino N, Kangawa K, et al. Endothelial cells actively synthesize and secrete adrenomedullin. Biochem Biophys Res Commun. 1994;201(3):1160-1166.</bib>
- Adrenomedullin: potential in physiology and pathophysiology.Life Sci. 2000; 66: 855-872
- Clinical value of pre-discharge bio-adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission.Eur J Heart Fail. 2020; 22: 683-691
- Plasma biomarker profiling in heart failure patients with preserved ejection fraction before and after spironolactone treatment: results from the Aldo-DHF trial.Cells. 2021; 10: 2796
- Prognostic significance of longitudinal clinical congestion pattern in chronic heart failure: insights from TIME-CHF trial.Am J Med. 2019; 132: e679-e692
- Do chronic heart failure patients receive optimal decongestive interventions in a real-life setting? Letter regarding the article ‘Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry’.Eur J Heart Fail. 2021; 23: 342
- Bioactive adrenomedullin a prognostic biomarker in patients with mild to moderate dyspnea at the emergency department: an observational study.Intern Emerg Med. 2021; ([online ahead of print]) (Jun 26)https://doi.org/10.1007/S11739-021-02776-Y
- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.Eur Heart J. 2021; 42: 3599-3726
- Venous congestion, endothelial and neurohormonal activation in acute decompensated heart failure: cause or effect?.Curr Heart Fail Rep. 2015; 12: 215-222
- Mid-regional pro-adrenomedullin improves disposition strategies for patients with acute dyspnoea: results from the BACH trial.Emerg Med J. 2013; 30: 633-637
- Integration of imaging and circulating biomarkers in heart failure: a consensus document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the European Society of Cardiology.Eur J Heart Fail. 2021; 23: 1577-1596
- A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2).BMJ Open. 2019; 9e024475
- Applications of machine learning approaches in emergency medicine; a review article.Arch Acad Emerg Med. 2019; 7: 34
Article Info
Publication History
Footnotes
Funding: The work was supported by the Research Council of Lithuania (Lietuvos mokslo taryba), grant No MIP-049/2015.
Conflicts of Interest: JS: speaker's honoraria from Boehringer Ingelheim, Bayer, Novartis, and consultancy fee from Servier. A Mikalauskas: speaker's honoraria from Boehringer Ingelheim and Bayer. EG: research grants from Sphingotec, Deltex Medical, and Retia Medical and consultancy fees from Magnisense, Roche Diagnostics, and Adrenomed. VJ: speaker's honoraria from Bayer, Pfizer, Servier, Boehringer Ingelheim and consultancy fee from Servier. EP: speaker's honoraria from Johnson & Johnson, Medis Pharma Lithuania. A Kavoliūnienė: speaker honoraria from Servier, Bayer, Berlin‐Chemie Menarini, Pfizer, and KRKA, travel grants from Servier, Bayer. A Mebazaa: speaker's honoraria from Orion, Novartis, Roche, and Servier. Fees as a member of advisory board or steering committee or research grant from 4TEEN4, Adrenomed, Abbott, Roche, Sanofi, and Sphyngotec. JC: personal fees from AstraZeneca, Boehringer Ingelheim, Sanofi, Amgen. All other authors have no conflicts of interest to declare.
Authorship: JS: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review & editing; A Mikalauskas: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review & editing; KČ: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review & editing; EG: Data curation, Investigation, Writing – original draft, Writing – review & editing; VJ: Data curation, Investigation, Writing – original draft, Writing – review & editing; EP: Data curation, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review & editing; IA-M: Conceptualization, Data curation, Methodology, Writing – original draft, Writing – review & editing; DK: Conceptualization, Investigation, Methodology, Project administration, Writing – original draft, Writing – review & editing; LB: Conceptualization, Data curation, Methodology, Resources, Writing – original draft, Writing – review & editing; MB: Conceptualization, Methodology, Writing – original draft, Writing – review & editing; DV: Data curation, Methodology, Writing – original draft, Writing – review & editing; IJ: Data curation, Formal analysis, Methodology, Writing – original draft, Writing – review & editing; JM: Conceptualization, Data curation, Investigation, Methodology, Writing – original draft, Writing – review & editing; KS: Data curation, Investigation, Methodology, Writing – original draft, Writing – review & editing; A Kukulskis: Conceptualization, Investigation, Methodology, Writing – original draft, Writing – review & editing; SD: Data curation, Methodology, Writing – original draft, Writing – review & editing; TŠ: Methodology, Writing – original draft, Writing – review & editing; NT: Methodology, Writing – original draft, Writing – review & editing; GP: Methodology, Writing – original draft, Writing – review & editing; AL: Data curation, Investigation, Methodology, Writing – original draft, Writing – review & editing; A Kavoliūnienė: Conceptualization, Data curation, Investigation, Methodology, Project administration, Supervision, Writing – original draft, Writing – review & editing; A Mebazaa: Conceptualization, Formal analysis, Investigation, Methodology, Project administration, Resources, Supervision, Writing – original draft, Writing – review & editing; JČ: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Writing – original draft, Writing – review & editing.
